Naveen Gupta joins LambdaTest as its Chief Financial Officer
6.4.2023 15:30:00 EEST | Business Wire | Press release
LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has announced the appointment of Naveen Gupta as its Chief Financial Officer. He comes with more than 35 years of experience across industries and brings a wealth of financial and strategic experience to LambdaTest, having held several executive roles at prominent companies in the past.
In his new role at LambdaTest, Naveen will lead the finance and accounting functions, helping to drive the company's growth and profitability. He will be responsible for financial planning, revenue projections, profit, business growth objectives, and risk management, among other responsibilities.
Naveen was most recently the CFO at Innovaccer, a Silicon Valley-based digital healthcare company. He was previously with Thomson Reuters, Pangea3 (acquired by Thomson Reuters), GlobalLogic India, and Xansa among other companies.
“Naveen comes with deep strategic expertise in scaling finance functions at technology companies and would be an invaluable asset for us. His three-and-a-half decades track record speaks for itself. Naveen will be our guiding light when it comes to growth and profitability. We are excited to welcome him to the LambdaTest rocketship,” said Asad Khan, CEO, LambdaTest.
“The innovation that LambdaTest is doing to disrupt the digital experience testing landscape excited me. The potential that such core innovation has is immense. Additionally, LambdaTest’s deep focus on partnerships to enable an integrated enterprise execution environment will fundamentally change the siloed approach to testing and will give companies a unified and streamlined experience,” said Naveen Gupta, CFO, LambdaTest. “The company leadership’s vision on productivity and efficiency is deep-rooted and my task is to carry forward the baton and strategically move towards growth and profitability. I’m looking forward to this journey.”
LambdaTest also recently announced the launch of its digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options–public cloud, single tenant, or on-premise.
About LambdaTest
LambdaTest is an intelligent unified digital experience testing cloud that helps businesses drastically reduce time to market through faster test execution, ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
Continuous Testing Cloud
LambdaTest's Continuous Testing Cloud allows enterprises to rapidly test and deploy changes to their web and mobile applications up to 70% faster, which helps to accelerate the development process and improve time-to-market.
Cross-browser Testing Cloud
Our cross-browser testing cloud allows users to test their websites and web applications on a wide variety of browsers, operating systems, and devices. With features such as real-time testing, responsive design testing, and debugging tools, it enables developers to ensure that their websites and web apps are compatible with different browsers, thereby providing a seamless user experience.
Real Device Cloud
With real device cloud, testers/developers can catch bugs early before their mobile apps go live. With LambdaTest's Real Devices Testing Cloud, teams can test unhandled errors, UI/UX, performance, and functionality of their apps before they get released into production. The teams can also test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV).
AI-powered Visual Regression Cloud
Ensuring consistent layouts, designs, and functionality of applications is crucial to deliver visually-perfect digital experiences. LambdaTest's visual regression cloud ensures that the visual appearance and functionality of an organization’s web applications remain consistent and error-free, ultimately improving the digital experience and business performance. Teams can get early insights on visual UI bugs before they release their applications to the customer. Testers/developers can run automated visual regression tests on 3000+ combinations of browsers & real devices to identify visual deviations.
AI-powered Integrated Test Intelligence
Test execution insights are critical for digital transformation as they provide enterprises with deeper insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's integrated test intelligence provides enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality. This can empower development teams with detailed and actionable test execution data and close the gap between data, insight, and action for better and faster decision-making.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005372/en/
Contact information
LambdaTest press office:
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom